TARBP1在非小细胞肺癌患者肿瘤组织中的表达及与生存预后的关系
|
摘要
目的探究TARBP1在非小细胞肺癌患者肿瘤组织中的表达及与生存预后的关系。方法选择我院2013年2月至2015年4月诊治的103例非小细胞肺癌患者作为研究对象,观察其手术后病理组织中TARBP1蛋白表达情况,探究TARBP1蛋白表达与非小细胞肺癌患者临床病理资料的关系。检测非小细胞肺癌组织及癌旁组织中TARBP1 mRNA表达量,探究TARBP1 mRNA在非小细胞肺癌患者3年预后诊断中的价值。分析非小细胞肺癌患者3年生存预后的独立影响因素。结果 TARBP1在非小细胞肺癌组织中阳性表达78例,占比75. 73%; TARBP1在癌旁组织中阳性表达23例,占比22. 33%,两组差异有统计学意义(P <0. 001)。TARBP1表达与非小细胞肺癌患者年龄、性别、肿瘤直径无关(P> 0. 05),与TNM分期、组织分化程度、病理类型和淋巴结转移有关(P <0. 05)。TARBP1 mRNA在非小细胞肺癌组织中的相对表达量与TARBP1 mRNA在癌旁组织中的相对表达量比较,差异有统计学意义(P <0. 001)。非小细胞肺癌术后3年生存患者与死亡患者接受根治术治疗时,非小细胞肺癌组织中TARBP1 mRNA表达量比较,差异有统计学意义(P <0. 001)。TARBP1 mRNA诊断非小细胞肺癌患者3年生存期的AUC为0. 891(95%CI:0. 723～0. 975),价值较高,可辅助评估非小细胞肺癌患者生存预后。单因素分析结果显示TNM分期、组织分化程度、肿瘤直径、淋巴结转移和TARBP1表达与非小细胞肺癌患者生存预后有关。多因素分析结果表明TNM分期及组织分化程度越高、肿瘤直径≥5 cm、淋巴结转移及TARBP1阳性表达,提示非小细胞肺癌患者预后较差。结论检测非小细胞肺癌组织中TARBP1蛋白表达有助于患者预后评估。
Objective To explore the expression of TARBP1 in tumor tissues of non-small cell lung cancer and its relationship with prognosis. Methods A total of 103 patients with non-small cell lung cancer who were diagnosed and treated in our Hospital from February 2013 to April 2015 were selected as the study subjects. The expression of TARBP1 protein in the pathological tissue was observed after surgery,and the relationship between TARBP1 protein expression and clinicopathological data of patients with non-small cell lung cancer were analyzed. The expression of TARBP1 mRNA in non-small cell lung cancer tissues and adjacent non-small cell lung cancer tissues was detected. The value of TARBP1 mRNA in three-year prognosis of patients with non-small cell lung cancer was explored.The independent influencing factors of 3-year survival prognosis in patients with non-small cell lung cancer was investigated. Results The positive expression of TARBP1 in non-small cell lung cancer was 78 cases,which accounted for 75. 73%. The positive expression of TARBP1 in the para cancerous tissues was 23 cases,accounting for22. 33%. The difference of the positive rate of TARBP1 in the two groups was statistically significant( P < 0. 001).The expression of TARBP1 was not related to age,sex and tumor diameter in non small cell lung cancer patients( P> 0. 05),which was related to TNM staging,degree of tissue differentiation,pathological type and lymph node metastasis( P < 0. 05). The relative expression of TARBP1 mRNA in non-small cell lung cancer tissues and the relative expression of TARBP1 mRNA in the para cancerous tissues were statistically significant( P < 0. 001). The expression of TARBP1 in non-small cell lung cancer( NSCLC) tissues was significantly different between survivors and dead patients at 3 years after operation( P < 0. 001). The AUC of TARBP1 mRNA for the diagnosis of non-small cell lung cancer patients with a 3-year survival period was 0. 891( 95% CI: 0. 723 to 0. 975). The value of TARBP1 mRNA was helpful for evaluating the survival of non-small cell lung cancer patients. Univariate analysis showed that TNM stage,histological differentiation,tumor diameter,lymph node metastasis,and TARBP1 expression were related to the prognosis of NSCLC patients. Multivariate analysis showed that the higher TNM stage and tissue differentiation,the diameter of tumors ≥ 5 cm,lymph node metastasis and TARBP1 positive expression suggested that the prognosis of NSCLC patients was poor. Conclusion The detection of TARBP1 protein expression in non-small cell lung cancer can contribute to the prognosis of patients.
Objective To explore the expression of TARBP1 in tumor tissues of non-small cell lung cancer and its relationship with prognosis. Methods A total of 103 patients with non-small cell lung cancer who were diagnosed and treated in our Hospital from February 2013 to April 2015 were selected as the study subjects. The expression of TARBP1 protein in the pathological tissue was observed after surgery,and the relationship between TARBP1 protein expression and clinicopathological data of patients with non-small cell lung cancer were analyzed. The expression of TARBP1 mRNA in non-small cell lung cancer tissues and adjacent non-small cell lung cancer tissues was detected. The value of TARBP1 mRNA in three-year prognosis of patients with non-small cell lung cancer was explored.The independent influencing factors of 3-year survival prognosis in patients with non-small cell lung cancer was investigated. Results The positive expression of TARBP1 in non-small cell lung cancer was 78 cases,which accounted for 75. 73%. The positive expression of TARBP1 in the para cancerous tissues was 23 cases,accounting for22. 33%. The difference of the positive rate of TARBP1 in the two groups was statistically significant( P < 0. 001).The expression of TARBP1 was not related to age,sex and tumor diameter in non small cell lung cancer patients( P> 0. 05),which was related to TNM staging,degree of tissue differentiation,pathological type and lymph node metastasis( P < 0. 05). The relative expression of TARBP1 mRNA in non-small cell lung cancer tissues and the relative expression of TARBP1 mRNA in the para cancerous tissues were statistically significant( P < 0. 001). The expression of TARBP1 in non-small cell lung cancer( NSCLC) tissues was significantly different between survivors and dead patients at 3 years after operation( P < 0. 001). The AUC of TARBP1 mRNA for the diagnosis of non-small cell lung cancer patients with a 3-year survival period was 0. 891( 95% CI: 0. 723 to 0. 975). The value of TARBP1 mRNA was helpful for evaluating the survival of non-small cell lung cancer patients. Univariate analysis showed that TNM stage,histological differentiation,tumor diameter,lymph node metastasis,and TARBP1 expression were related to the prognosis of NSCLC patients. Multivariate analysis showed that the higher TNM stage and tissue differentiation,the diameter of tumors ≥ 5 cm,lymph node metastasis and TARBP1 positive expression suggested that the prognosis of NSCLC patients was poor. Conclusion The detection of TARBP1 protein expression in non-small cell lung cancer can contribute to the prognosis of patients.
引文
[1]牛永亮,李小波,王波,等.非小细胞肺癌组织中Hsp90β和survivin的表达及其临床意义[J].临床肺科杂志,2018,23(4):598-603.
[2] BOUJIBAR F,BONNEVIE T,DEBEAUMONT D,et al. Impact of prehabilitation on morbidity and mortality after pulmonary lobectomy by minimally invasive surgery:a cohort study[J]. J Thorac Dis,2018,10(4):2240-2248.
[3] KIM H,KWON H J,PARK S Y,et al. Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer[J]. PLo S One,2018,13(6):e0198634.
[4] BRITSCHGI C,RIESTERER O,BURGER I A,et al. Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer[J].Radiat Oncol,2018,13(1):102.
[5] WALTER R F H,ROZYNEK P,CASJENS S,et al. Methylation of L1RE1,RARB,and RASSF1 function as possible biomarkers for the differential diagnosis of lung cancer[J]. PLo S One,2018,13(5):e0195716.
[6] GUAN W J,LI S Y,ZHONG N S. Effects of para-toluenesulfonamide intratumoral injection on pulmonary adenoid cystic carcinoma complicating with severe central airway obstruction:a 5-year follow-up study[J]. J Thorac Dis,2018,10(4):2448-2455.
[7] ZHU L,JIANG L,YANG J,et al. Clinical characteristics and prognosis of patients with lung adenosquamous carcinoma after surgical resection:results from two institutes[J]. J Thorac Dis,2018,10(4):2397-2402.
[8]佟娟.血清中趋化素在非小细胞肺癌中的表达和预后意义[J].临床肺科杂志,2018,23(3):417-420.
[9] YANG X,LI M,YANG X,et al. Uniport versus multiport video-assisted thoracoscopic surgery in the perioperative treatment of patients with T1-3N0M0 non-small cell lung cancer:a systematic review and meta-analysis[J]. J Thorac Dis,2018,10(4):2186-2195.
[10] PARK H J,PARK H S,CHA Y J,et al. Efficacy of adjuvant chemotherapy for completely resected stageⅠB non-small cell lung cancer:a retrospective study[J]. J Thorac Dis,2018,10(4):2279-2287.
[11] LIANG H,PAN Z,WANG W,et al. The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy:a literature-based pooled analysis[J]. J Thorac Dis,2018,10(4):2311-2320.
[12] LIN J,XIA J,CHEN Y T,et al. H9N2 avian influenza virus enhances the immune responses of BMDCs by down-regulating miR29c[J]. Vaccine,2017,35(5):729-737.
[13] CRAWFORD D W,BLAKELEY B D,CHEN P H,et al. An Evolved RNA Recognition Motif That Suppresses HIV-1 Tat/TARDependent Transcription[J]. ACS Chem Biol,2016,11(8):2206-2215.
[14] ELSEMMAN I E,MARDINOGLU A,SHOAIE S,et al. Systems biology analysis of hepatitis C virus infection reveals the role of copy number increases in regions of chromosome 1q in hepatocellular carcinoma metabolism[J]. Mol Biosyst,2016,12(5):1496-1506.
[15] YE J,WANG J,TAN L,et al. Expression of protein TARBP1 in human hepatocellular carcinoma and its prognostic significance[J]. Int J Clin Exp Pathol,2015,8(8):9089-9096.
[16] YE J,WANG J,ZHANG N,et al. Expression of TARBP1 protein in human non-small-cell lung cancer and its prognostic significance[J]. Oncol Lett,2018,15(5):7182-7190.
[17] DENG H Y,LI G,LUO J,et al. Novel biologic factors correlated to visceral pleural invasion in early-stage non-small cell lung cancer less than 3cm[J]. J Thorac Dis,2018,10(4):2357-2364.
[2] BOUJIBAR F,BONNEVIE T,DEBEAUMONT D,et al. Impact of prehabilitation on morbidity and mortality after pulmonary lobectomy by minimally invasive surgery:a cohort study[J]. J Thorac Dis,2018,10(4):2240-2248.
[3] KIM H,KWON H J,PARK S Y,et al. Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer[J]. PLo S One,2018,13(6):e0198634.
[4] BRITSCHGI C,RIESTERER O,BURGER I A,et al. Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer[J].Radiat Oncol,2018,13(1):102.
[5] WALTER R F H,ROZYNEK P,CASJENS S,et al. Methylation of L1RE1,RARB,and RASSF1 function as possible biomarkers for the differential diagnosis of lung cancer[J]. PLo S One,2018,13(5):e0195716.
[6] GUAN W J,LI S Y,ZHONG N S. Effects of para-toluenesulfonamide intratumoral injection on pulmonary adenoid cystic carcinoma complicating with severe central airway obstruction:a 5-year follow-up study[J]. J Thorac Dis,2018,10(4):2448-2455.
[7] ZHU L,JIANG L,YANG J,et al. Clinical characteristics and prognosis of patients with lung adenosquamous carcinoma after surgical resection:results from two institutes[J]. J Thorac Dis,2018,10(4):2397-2402.
[8]佟娟.血清中趋化素在非小细胞肺癌中的表达和预后意义[J].临床肺科杂志,2018,23(3):417-420.
[9] YANG X,LI M,YANG X,et al. Uniport versus multiport video-assisted thoracoscopic surgery in the perioperative treatment of patients with T1-3N0M0 non-small cell lung cancer:a systematic review and meta-analysis[J]. J Thorac Dis,2018,10(4):2186-2195.
[10] PARK H J,PARK H S,CHA Y J,et al. Efficacy of adjuvant chemotherapy for completely resected stageⅠB non-small cell lung cancer:a retrospective study[J]. J Thorac Dis,2018,10(4):2279-2287.
[11] LIANG H,PAN Z,WANG W,et al. The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy:a literature-based pooled analysis[J]. J Thorac Dis,2018,10(4):2311-2320.
[12] LIN J,XIA J,CHEN Y T,et al. H9N2 avian influenza virus enhances the immune responses of BMDCs by down-regulating miR29c[J]. Vaccine,2017,35(5):729-737.
[13] CRAWFORD D W,BLAKELEY B D,CHEN P H,et al. An Evolved RNA Recognition Motif That Suppresses HIV-1 Tat/TARDependent Transcription[J]. ACS Chem Biol,2016,11(8):2206-2215.
[14] ELSEMMAN I E,MARDINOGLU A,SHOAIE S,et al. Systems biology analysis of hepatitis C virus infection reveals the role of copy number increases in regions of chromosome 1q in hepatocellular carcinoma metabolism[J]. Mol Biosyst,2016,12(5):1496-1506.
[15] YE J,WANG J,TAN L,et al. Expression of protein TARBP1 in human hepatocellular carcinoma and its prognostic significance[J]. Int J Clin Exp Pathol,2015,8(8):9089-9096.
[16] YE J,WANG J,ZHANG N,et al. Expression of TARBP1 protein in human non-small-cell lung cancer and its prognostic significance[J]. Oncol Lett,2018,15(5):7182-7190.
[17] DENG H Y,LI G,LUO J,et al. Novel biologic factors correlated to visceral pleural invasion in early-stage non-small cell lung cancer less than 3cm[J]. J Thorac Dis,2018,10(4):2357-2364.